AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32910338 — intervention group
Group type: EXPERIMENTAL
Intervention: pegilodecakin+FOLFOX
Number of subjects: 39
Study 32910360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 91
Study 32910531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 710
Study 32910531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 710
Study 32910531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (both doses)
Number of subjects: 710
Study 32910531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 32910531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 710
Study 32910776 — intervention group
Group type: EXPERIMENTAL
Intervention: rs738409(G) SNP variant
Number of subjects: 917
Study 32910776 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRD cluster members
Number of subjects: 917
Study 32910816 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) assessed via accelerometer
Number of subjects: 7280
Study 32911050 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Scientific ImageReady ICD (n = 39) or CRT-D (n = 191)
Number of subjects: 230
Study 32911050 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI Protection Mode turned on
Number of subjects: 230
Study 32911703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytochrome P450 intervention, details not specified
Number of subjects: 0
Study 32912180 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 1, 2, or 4 mg granules orally
Number of subjects: 99
Study 32912268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir) for prevention of mother to child transmission (PMTCT) of hepatitis B virus (HBV)
Number of subjects: 171
Study 32912268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir)
Number of subjects: 171
Study 32912364 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial Hypertension (AH) present
Number of subjects: 319
Study 32912364 — intervention group
Group type: COMPARATOR
Intervention: No Arterial Hypertension (AH)
Number of subjects: 319
Study 32912364 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated blood pressure levels on BP Holter 1 month after discharge
Number of subjects: 319
Study 32912460 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve intervention (TTVI)
Number of subjects: 333
Study 32912460 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive or torrential TR
Number of subjects: 333
Study 32912460 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural success
Number of subjects: 333
Study 32912472 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-cap fibroatheromas (TCFAs)
Number of subjects: 131
Study 32912472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrous plaques
Number of subjects: 131
Study 32912472 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute coronary syndromes (ACS)
Number of subjects: 131
Study 32912472 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without acute coronary syndromes (ACS)
Number of subjects: 131
Study 32912664 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (WP) monotherapy
Number of subjects: 188
Study 32912788 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid (SUA) levels
Number of subjects: 2569
Study 32912957 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term breast cancer survivors
Number of subjects: 0
Study 32912957 — intervention group
Group type: COMPARATOR
Intervention: Women without breast cancer (control group)
Number of subjects: 0
Study 32913286 — intervention group
Group type: EXPERIMENTAL
Intervention: sapanisertib 5 mg QD
Number of subjects: 31
Study 32913286 — intervention group
Group type: EXPERIMENTAL
Intervention: sapanisertib 40 mg QW
Number of subjects: 31
Study 32913286 — intervention group
Group type: EXPERIMENTAL
Intervention: sapanisertib 30 mg QW
Number of subjects: 31
Study 32913286 — intervention group
Group type: EXPERIMENTAL
Intervention: sapanisertib QD, QW, QD × 3dQW, QD × 5dQW
Number of subjects: 31
Study 32913286 — intervention group
Group type: EXPERIMENTAL
Intervention: sapanisertib
Number of subjects: 31
Study 32913660 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth resilience-building intervention
Number of subjects: 62
Study 32913914 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions targeting lifestyle and cardiovascular disease risk
Number of subjects: 0
Study 32913985 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq classifiers for hormone responsiveness
Number of subjects: 3678
Study 32913985 — intervention group
Group type: EXPERIMENTAL
Intervention: MGC hormone-responsive classifier
Number of subjects: 3678
Study 32913985 — intervention group
Group type: COMPARATOR
Intervention: RNA-seq classifiers
Number of subjects: 3678
Study 32914038 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arms of innovative glioblastoma therapy
Number of subjects: 0
Study 32914038 — intervention group
Group type: COMPARATOR
Intervention: Standard concurrent temozolomide and radiation therapy followed by adjuvant temozolomide (Control)
Number of subjects: 0
Study 32914172 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intravaginal ring (IVR) delivering 40 µg LNG per day
Number of subjects: 1471
Study 32914172 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intravaginal ring (IVR)
Number of subjects: 1471
Study 32914187 — intervention group
Group type: EXPERIMENTAL
Intervention: BDG concentration >100 pg/mL
Number of subjects: 0
Study 32914187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple (≥2) positive results >100 pg/mL or a BDG concentration increasing >100 pg/mL
Number of subjects: 0
Study 32914187 — intervention group
Group type: EXPERIMENTAL
Intervention: BDG concentration >100 pg/mL in patients with IC
Number of subjects: 0
Study 32914187 — intervention group
Group type: EXPERIMENTAL
Intervention: BDG concentration ≤100 pg/mL in patients with IC
Number of subjects: 0
Study 32914187 — intervention group
Group type: EXPERIMENTAL
Intervention: BDG concentration >100 pg/mL in patients without IC
Number of subjects: 0
Study 32914187 — intervention group
Group type: COMPARATOR
Intervention: Micafungin
Number of subjects: 0
Study 32914581 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 25-μg ODTs
Number of subjects: 503
Study 32914581 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 50-μg ODTs
Number of subjects: 503
Study 32914581 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin ODTs (25 and 50 μg)
Number of subjects: 503
Study 32914672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhyperemic pressure ratios (NHPRs) including instantaneous wave-free ratio, resting full-cycle ratio, and diastolic pressure ratio ≤0.89
Number of subjects: 435
Study 32914672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR) ≤0.80
Number of subjects: 435
Study 32914672 — intervention group
Group type: COMPARATOR
Intervention: Negative NHPRs
Number of subjects: 435
Study 32914672 — intervention group
Group type: COMPARATOR
Intervention: Negative FFR
Number of subjects: 435
Study 32915072 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation levels in patients with COVID-19
Number of subjects: 0
Study 32915162 — intervention group
Group type: EXPERIMENTAL
Intervention: Work2Prevent (W2P) employment intervention program
Number of subjects: 41
Study 32915349 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoamlodipine maleate (n=5018)
Number of subjects: 10031
Study 32915349 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate (n=5013)
Number of subjects: 10031
Study 32915349 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoamlodipine maleate
Number of subjects: 10031
Study 32915384 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab subcutaneous (DARA SC) 1,800 mg
Number of subjects: 6
Study 32915419 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (75 mg escalating to 150 mg TIW for 2 weeks, then 50 mg TIW) + Prednisone (co-administered for 2 weeks in Cycle 1)
Number of subjects: 28
Study 32915419 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (75 mg TIW)
Number of subjects: 28
Study 32915419 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (100 mg BIW)
Number of subjects: 28
Study 32915679 — intervention group
Group type: EXPERIMENTAL
Intervention: CaboNivo (cabozantinib 40 mg/d plus nivolumab 3 mg/kg)
Number of subjects: 54
Study 32915679 — intervention group
Group type: EXPERIMENTAL
Intervention: CaboNivoIpi (cabozantinib 40 mg/d, nivolumab 3 mg/kg, and ipilimumab 1 mg/kg)
Number of subjects: 54
Study 32915950 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV5 gene therapy producing B-domain-deleted FVIII (FVIII-SQ)
Number of subjects: 2
Study 32915950 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgene-produced FVIII-SQ
Number of subjects: 2
Study 32915950 — intervention group
Group type: COMPARATOR
Intervention: CS activity
Number of subjects: 2
Study 32915978 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Number of subjects: 41
Study 32916296 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol fixed-dose combination (5 μg/5 μg)
Number of subjects: 12
Study 32916310 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonertinib (HS-10296) at doses of 55, 110, 220 mg
Number of subjects: 120
Study 32916704 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver-directed gene therapy
Number of subjects: 8
Study 32916704 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital-induced attacks
Number of subjects: 8
Study 32916704 — intervention group
Group type: COMPARATOR
Intervention: AIP patients
Number of subjects: 8
Study 32917138 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Stress Questionnaire combined with feedback at consultation
Number of subjects: 23
Study 32917138 — intervention group
Group type: COMPARATOR
Intervention: Ordinary consultative way of working
Number of subjects: 23
Study 32917168 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic endometrial dating on day PO + 7 for RIF patients
Number of subjects: 205
Study 32917168 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional frozen-thawed embryo transfer (FET) after endometrial biopsy
Number of subjects: 205
Study 32917192 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide gel
Number of subjects: 25
Study 32917192 — intervention group
Group type: COMPARATOR
Intervention: 37.5% hydrogen peroxide gel
Number of subjects: 25
Study 32917289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section delivery
Number of subjects: 31
Study 32917289 — intervention group
Group type: COMPARATOR
Intervention: No environmental risk factors
Number of subjects: 31
Study 32917344 — intervention group
Group type: COMPARATOR
Intervention: Progression of valvular calcification (VC) at 1 site (AVC or MAC)
Number of subjects: 5591
Study 32917344 — intervention group
Group type: COMPARATOR
Intervention: Progression of valvular calcification (VC) at 2 sites (AVC and MAC)
Number of subjects: 5591
Study 32917344 — intervention group
Group type: COMPARATOR
Intervention: Progression of aortic valve calcification (AVC)
Number of subjects: 5591
Study 32917344 — intervention group
Group type: COMPARATOR
Intervention: Progression of mitral annular calcification (MAC)
Number of subjects: 5591
Study 32917344 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of valvular calcification (VC)
Number of subjects: 5591
Study 32917355 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese individuals with modified Mallampati classification of 4
Number of subjects: 29
Study 32917355 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese individuals
Number of subjects: 29
Study 32917537 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (DS-8201a)
Number of subjects: 0
Study 32917626 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum ACE
Number of subjects: 996
Study 32917626 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphopaenia
Number of subjects: 996
Study 32917626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of elevated serum ACE and lymphopaenia
Number of subjects: 996
Study 32917626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of elevated serum ACE and lymphopaenia in patients aged ≤50 years
Number of subjects: 996
Study 32917626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of elevated serum ACE and lymphopaenia in granulomatous uveitis
Number of subjects: 996
Study 32917807 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditionally defined status epilepticus (TSE)
Number of subjects: 2197
Study 32917807 — intervention group
Group type: EXPERIMENTAL
Intervention: Operationally defined status epilepticus (OSE)
Number of subjects: 2197
Study 32918045 — intervention group
Group type: EXPERIMENTAL
Intervention: SAF-189s, a new-generation ROS1/ALK inhibitor
Number of subjects: 0
Study 32918045 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib (first-generation ROS1 inhibitor)
Number of subjects: 0
Study 32918305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (Left ventricular disease)
Number of subjects: 800
Study 32918305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (Patent foramen ovale)
Number of subjects: 800
Study 32918305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 (Arterial disease)
Number of subjects: 800
Study 32918305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 4 (Atrial cardiopathy)
Number of subjects: 800
Study 32918305 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 800
Study 32919178 — intervention group
Group type: EXPERIMENTAL
Intervention: apixaban 10 mg bid for seven days, then 5 mg bid for six months
Number of subjects: 298
Study 32919398 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromelanin-sensitive MRI (NM-MRI)
Number of subjects: 33
Study 32919398 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA treatment for 3 weeks
Number of subjects: 33
Study 32919458 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate initial antimicrobial regimens in clinical failure (CF) group
Number of subjects: 3011
Study 32919458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical failure (CF)
Number of subjects: 3011
Study 32919458 — intervention group
Group type: COMPARATOR
Intervention: Clinical success (CS)
Number of subjects: 3011
Study 32919458 — intervention group
Group type: EXPERIMENTAL
Intervention: CF patients
Number of subjects: 3011
Study 32919458 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant therapy
Number of subjects: 3011
Study 32919461 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Coma-Recovery Scale-Revised (CRS-R) assessment
Number of subjects: 137
Study 32919461 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Coma-Recovery Scale-Revised (CRS-R) assessments (≥5 times within a week)
Number of subjects: 137
Study 32919461 — intervention group
Group type: COMPARATOR
Intervention: Clinical consensus diagnosis of EMCS
Number of subjects: 137
Study 32919527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular extended-dose fulvestrant 500 mg (Cohort A)
Number of subjects: 1034
Study 32919527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral neratinib 240 mg and intramuscular standard-dose fulvestrant (Cohort B)
Number of subjects: 1034
Study 32919527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capivasertib 400 mg plus intramuscular standard-dose fulvestrant (Cohort C)
Number of subjects: 1034
Study 32919527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capivasertib 480 mg (Cohort D)
Number of subjects: 1034
Study 32919861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 23
Study 32919861 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-obese women (control)
Number of subjects: 23
Study 32920226 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (α-tocopherol, αT) 200-800 IU/d for 24 weeks
Number of subjects: 20
Study 32920226 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (α-tocopherol, αT)
Number of subjects: 20
Study 32920226 — intervention group
Group type: EXPERIMENTAL
Intervention: Redox-silenced methoxy-αT
Number of subjects: 20
Study 32920226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidative stress (OS)
Number of subjects: 20
Study 32920453 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS) after PAP therapy
Number of subjects: 134
Study 32920453 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of Wakefulness Test (MWT)
Number of subjects: 134
Study 32920652 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual drug level (RDL) feedback from counselors
Number of subjects: 42
Study 32920652 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor communication strategies
Number of subjects: 42
Study 32920652 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback on adherence measures
Number of subjects: 42
Study 32920723 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAT model
Number of subjects: 287
Study 32921507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacel vaccine (Group 1)
Number of subjects: 1195
Study 32921507 — intervention group
Group type: COMPARATOR
Intervention: Other brand of vaccine (Group 2)
Number of subjects: 1195
Study 32921507 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed vaccinations
Number of subjects: 1195
Study 32921790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 127
Study 32921790 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 127
Study 32921790 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 127
Study 32922454 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring combined with IMS-based weekly feedback and reminders
Number of subjects: 96
Study 32922454 — intervention group
Group type: COMPARATOR
Intervention: Electronic monitoring only (control group)
Number of subjects: 96
Study 32922577 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min massage intervention
Number of subjects: 12
Study 32922577 — intervention group
Group type: COMPARATOR
Intervention: Reading control
Number of subjects: 12
Study 32922827 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (treatment group)
Number of subjects: 10
Study 32922827 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 10
Study 32923144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 294
Study 32923151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) + Azithromycin (AZI)
Number of subjects: 0
Study 32923156 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL therapy alone
Number of subjects: 10
Study 32923156 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL combined with autologous tumor lysate-loaded DC vaccination
Number of subjects: 10
Study 32923156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/fludarabine preconditioning and intravenous IL-2 after TIL transfer
Number of subjects: 10
Study 32923156 — intervention group
Group type: EXPERIMENTAL
Intervention: DC vaccine (five intradermal injections)
Number of subjects: 10
Study 32923446 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Qigong
Number of subjects: 0
Study 32923446 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32923686 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot thermometry with mHealth-based supplementation
Number of subjects: 0
Study 32923686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32923686 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32923849 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing
Number of subjects: 517
Study 32923850 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisolone (AAP)
Number of subjects: 0
Study 32923850 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus dexamethasone
Number of subjects: 0
Study 32923850 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32923853 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic genomic characterization
Number of subjects: 1045
Study 32923921 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-rich vegetable oil (10 mL/d)
Number of subjects: 18
Study 32923921 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid-rich oil (OA-oil)
Number of subjects: 18
Study 32924093 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-88 (230 mg BID), methoxsalen (10 mg), phenytoin (50 mg), sirolimus (0.5 mg)
Number of subjects: 21
Study 32924093 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-88
Number of subjects: 21
Study 32924568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-Acting Insulin Aspart
Number of subjects: 0
Study 32924568 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32924725 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic interviews
Number of subjects: 0
Study 32924952 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer navigation and text messaging interventions to support PrEP persistence and adherence.
Number of subjects: 0
Study 32924952 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention with three messages per day.
Number of subjects: 0
Study 32924986 — intervention group
Group type: EXPERIMENTAL
Intervention: ADXBLADDER test for MCM5 expression
Number of subjects: 119
Study 32924986 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 119
Study 32925091 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 3B (muscles innervated by lower lumbar and sacral segments)
Number of subjects: 23
Study 32925091 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength assessed using Medical Research Council (MRC) score
Number of subjects: 23
Study 32925091 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance walked on the 6-minute walk test (6MWT)
Number of subjects: 23